News

BlogsPosts
Press Release
Replicel Life Sciences Continues Restructuring with Share Structure Consolidation
VANCOUVER, BC – July 22, 2016 – RepliCel Life Sciences Inc. (“RepliCel” or the “Company”)
BlogsPosts
Press Release
RepliCel’s Cell Therapy for Pattern Baldness Proceeds to Clinical Trial Launch in Japan
VANCOUVER, BC – July 21, 2016 – RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSXV: RP)
BlogsPosts
Press Release
Replicel Life Sciences Extends Warrant Expiry Dates and Amends Warrant Exercise Price
VANCOUVER, BC – April 29, 2016 – RepliCel Life Sciences Inc. (“RepliCel” or the “Company”)
BlogsPosts
Press Release
RepliCel Life Sciences conducts formal consultation review with Japan’s PMDA and receives unprecedented review fee reduction
Japan’s Pharmaceuticals and Medical Devices Agency reviews RepliCel’s pre-clinical, quality, and manufacturing data for its
BlogsPosts
Press Release
RepliCel Life Sciences Finishes Enrolment for its Tendon Repair and Skin Rejuvenation Clinical Trials
Results from both trials will support commercialization initiatives, partner discussions and continued clinical development VANCOUVER, BC
BlogsPosts
Press Release
Replicel Life Sciences Applies to Amend Warrant Exercise Price and Extend Warrant Expiry Dates
VANCOUVER, BC – April 8, 2016 – RepliCel Life Sciences Inc. (“RepliCel” or the “Company”)
BlogsPosts
Press Release
RepliCel Life Sciences Announces Restructuring, Cost Reductions and Closing of Private Placement
VANCOUVER, BC – April 6, 2016 – RepliCel Life Sciences Inc. (“RepliCel” or the “Company”)
BlogsPosts
As Seen In
Shiseido to trial baldness ‘cure’ for planned commercial launch in 2018
Find full article here online, at The Asahi Shimbun.
BlogsPosts
As Seen In
Embrace Low-Cap Biotech for High Gains: Eden Rahim of Next Edge Capital
Source: George S. Mack of The Life Sciences Report (3/2/16) View the
BlogsPosts
Press Release
Investor Hub News Releases Financials Analyst Coverage Events SEDAR Filings EDGAR Filings Presentations & Fact Sheets Corporate Governance Info Request Videos RepliCel Life Sciences Inc. Announces Closing of Warrant Incentive Program
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED
BlogsPosts
Press Release
RepliCel Announces CEO Update
Milestones for 2016 include two clinical trial readouts, finalizing RCI-02 for a 2017 product launch,
BlogsPosts
Press Release
RepliCel Life Sciences Announces Warrant Exercise Incentive Program
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY,
BlogsPosts
Event
2016 EBD Biotech Showcase
RepliCel presented and conducted one-on-one partnering meetings.
BlogsPosts
Press Release
RepliCel Receives European Patent for its Innovative Dermal Injector Technology
RCI-02 injector device promises the potential for unparalleled injection precision, the use of less anesthetic
BlogsPosts
Press Release
RepliCel Life Sciences Inc. Announces Closing of Second Tranche of Private Placement
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED
BlogsPosts
Press Release
RepliCel Announces Completion of First Injections in Clinical Trial of RCS-01 for Skin Aging and UV-Damaged Skin
Phase 1 clinical trial investigating the use of a patient-specific cell-based dermal rejuvenation product (RCS-01)
BlogsPosts
Press Release
RepliCel Life Sciences Announces Leadership Transition
Lee Buckler, former VP Business & Corporate Development, appointed CEO President & Director; David Hall
BlogsPosts
Press Release
RepliCel Life Sciences Inc. Announces Closing of First Tranche of Private Placement
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR
BlogsPosts
As Seen In
How Japan ‘Changed the System’
Japan’s Bold Steps By: Iain Marlow ASUKE, JAPAN The Globe and Mail Last
BlogsPosts
Event
RepliCel Executives to Present at 9th World Congress for Hair Research in Miami
Conference brings together hair biologists, dermatologists, cosmetic scientists and leading biotech companies to discuss the
Previous 1 .. 2 3 4 5 6 .. 12Next

DISCLAIMER:
The information in these press releases is historical in nature, has not been updated, and is current only to the date indicated in the particular press release. This information may no longer be accurate and therefore you should not rely on the information contained in these press releases. To the extent permitted by law, RepliCel Life Sciences Inc. and its employees, agents and consultants exclude all liability for any loss or damage arising from the use of, or reliance on, any such information, whether or not caused by any negligent act or omission.

THIRD PARTY CONTENT
Please note that any opinion, estimates or forecasts made by the authors of these statements are theirs alone and do not represent opinions, forecasts or predictions of RepliCel Life Sciences Inc. or its management. RepliCel Life Sciences Inc. does not, by its reference or distribution of these links imply its endorsement of, or concurrence with, such information, conclusions or recommendations.